Summary: Carcinoembryonic antigen (CEA) is a potential target for antigen-specific immunotherapy, as it is frequently overexpressed in human carcinomas. Moreover, an epitope derived from CEA, designated CAP1 (YLSGANLNL), has been proposed as naturally processed and presented by tumors in the human leukocyte antigen (HLA)-A*0201 context. Our aim was to fully characterize and assess the clinical relevance of the HLA-A*0201-restricted cytotoxic T lymphocyte (CTL) response against CEA. Stable and potent artificial antigen presenting cells (AAPCs) were used to evaluate T-cell response against CEA. These cells efficiently activate CTLs against tumor-derived epitopes after transduction with the antigenic peptides or full-length proteins. We found that AAPCs genetically modified to express CAP1, the agonist peptide CAP1-6D, or the whole CEA protein were not able to activate CAP1-specific CTLs from HLA-A*0201 + healthy donors or patients with colorectal carcinoma, even after multiple stimulations. In addition, we showed that a CAP1-specific T-cell clone, obtained after multiple stimulations of T cells of a HLA-A*0201 + healthy donor in vitro with autologous antigen presenting cells, recognized CEA À HLA-A*0201 + tumors transduced with a minigene encoding CAP1 but failed to react against HLA-A*0201 + tumor cells expressing CEA. Finally, AAPCs expressing the whole CEA protein did not induce any specific CTL response against CEA + HLA-A*0201 + tumor cells highlighting the potential difficulty of mounting an efficacious T-cell response against this autoantigen. Altogether, our data indicate that CAP1 is not efficiently processed and presented by CEA + tumor cells, and therefore, is not an appropriate target for T-cellbased immunotherapy.
Key Words: carcinoembryonic antigen, CAP1 peptide, T-cell-based immunotherapy, artificial antigen presenting cells, cytotoxic T cells, retroviral transduction (J Immunother 2010;00:000-000) I n human colorectal cancer (CRC), several recent studies have highlighted the importance of the immune system in controlling tumor development. Indeed, analysis of tumorinfiltrating T lymphocytes in CRC has shown that a high density of CD3 + T cells within tumor biopsies correlates with a favorable prognosis. 1, 2 The presence of functional tumor-associated antigen-reactive T cells in situ is another strong argument supporting the immunogenicity of CRC. 3, 4 These data have enhanced interest of T-cell-based immunotherapy as a potential approach for the treatment of CRCs. CD8 + cytotoxic T lymphocytes (CTLs) are the main antitumor effectors and are able to recognize and lyse specifically malignant cells expressing the relevant tumor-associated antigens that are processed into peptides presented by major histocompatibility complex (MHC) class I molecules. Tumor-specific recognition is mediated through interaction of the clonal T-cell receptors on CTLs with these specific MHC class I-peptide complexes on tumor cells. 5 Carcinoembryonic antigen (CEA) also known as CEA-CAM5 or CD66e is a 180 KDa intercellular adhesion glycoprotein, expressed at high levels during oncofetal development and at low levels in normal colonic epithelium. 6 CEA represents an attractive target for tumor immunotherapy because it is commonly overexpressed by a wide range of carcinomas such as CRC, gastric, pancreas, breast and nonsmall cell lung cancers. 7 The HLA-A*0201-restricted CTL peptide CAP1 (YLSGANLNL 605À 613 ) has been defined as an epitope derived from CEA. CAP1 peptide has been determined by reverse immunology using a predictive algorithm and selected to sensitize peripheral blood lymphocytes from patients vaccinated with a recombinant vaccinia virus encoding CEA. 8 In this aforementioned study, CTLs were able to recognize and kill cells presenting the relevant peptide and tumor cells expressing CEA. An agonist epitope, named CAP1-6D (YLSGADLNL), was derived from the native peptide CAP1 by amino acid substitution. 9 Most vaccine approaches targeting CAP1 epitope or CEA antigen are based on injection of vaccinia virus encoding CEA or of human dendritic cells (DCs) either pulsed with CAP1 or CAP1-6D peptide or transfected with mRNA encoding CEA [see for review response and the efficacy of CEA-specific CTLs in vitro and in vivo has not been accurately evaluated yet. 12, 13 To facilitate expansion of clinically relevant quantities of functional CTLs specific for viral or tumor antigens, we have developed a strategy based on the construction of potent and stable artificial antigen presenting cells (AAPCs). [14] [15] [16] These AAPCs are murine fibroblasts genetically engineered to express the human b2-microglobulin noncovalently linked to the HLA-A*0201 molecule and the 3 essential costimulatory molecules B7.1 (CD80), ICAM-1 (CD54), and LFA-3 (CD58). 17, 18 These cells have already been described as being as effective as peptide-pulsed autologous DCs to stimulate T cells in the context of a single HLA molecule.
14 Moreover, these AAPCs are able to process and present immunogenic epitopes derived from full-length protein as demonstrated for viral proteins, such as the cytomegalovirus protein pp65 15 and tumor antigens, such as the human telomerase reverse transcriptase (hTERT) 16 or the Wilms' tumor antigen 1 (unpublished data). In this study, we took advantage of the AAPCs to dissect the HLA-A*0201-restricted CTL response against CEA, and showed that CEA-derived peptide CAP1 was not a suitable target for T-cell-based immunotherapy.
MATERIALS AND METHODS

Peptides
The following HLA-A*0201-binding peptides were used: flu matrix protein (FMP) 58-66 (GILGFVFTL, irrelevant peptide), CEA 605-613 (YLSGANLNL, CAP1 peptide), CAP1-6D (YLSGADLNL), NY-ESO-1 157-165 (SLL MWITQ, NYpep), MART-1 [27] [28] [29] [30] [31] [32] [33] [34] [35] (AAGIGILTV, M1pep), and MART-1 modified (ELAGIGILTV, M1mod). Peptides were synthesized in the laboratory (Inserm U413) and dissolved first in DMSO (Sigma-Aldrich, St Quentin Fallavier, France) 1vol and then adjusted with PBS 19vol to a final concentration of 1 mg/mL.
Cell Lines
The CRC cell lines SW620 and T84 were kindly provided by J. Le Pendu (Inserm U892, Nantes, France) and JC. Cuber (Inserm U45, Lyon, France). The CRC Colo205, HT-29, SW403 and SW1463, the TAP-deficient lymphoma T2, and the fibroblast NIH/3T3 cell lines were purchased from ATCC (Manassas, VA). The melanoma M102 and M140 and the CRC SW707 cell lines were the kind gift of N. Labarrie`re (Inserm U892). The renal cell carcinoma cell line R104 was established in the laboratory (EE 341, Rennes, France). All cell lines were cultured in standard recommended supplemented medium. H29/293GPG packaging cell line 19 was cultured with DMEM supplemented with 10% FCS, G418 0.3 mg/mL, puromycin 2 mg/mL and tetracycline 1 mg/mL (Sigma-Aldrich).
T-cell Clones
The anti-CAP1 T-cell clone (8-7B9) was generated from peripheral blood mononuclear cells (PBMCs) of a HLA-A*0201 + healthy donor by in vitro peptide sensitization, as earlier described. 20 Briefly, monocyte-derived DCs pulsed with 5 mg/mL CAP1-6D peptide were used to stimulate autologous PBMCs. Anti-CAP1 bulk culture was restimulated numerous times with peptide-pulsed autologous-irradiated PBMCs. [27] [28] [29] [30] [31] [32] [33] [34] [35] T-cell clone M77-84, 21 both HLA-A*0201 restricted, were kindly provided by N. Labarrie`re. T-cell clones were expanded in RPMI 1640 supplemented with 5% human serum, 300 IU/mL IL-2 (Proleukin, Chiron, Suresnes, France), and 1 mg/mL PHA (Sigma-Aldrich).
Vector Construction cDNAs were cloned into a gammaretrovirus-derived SFG vector backbone. 22 Dicistronic vectors containing the puromycin-N-acetyltransferase open reading frame 14 cloned downstream of an internal ribosome entry site 23 were used to express the different antigenic peptides and proteins. The human CD8a leader sequence was added in 5 0 of the peptidic sequences to target the peptides to the endoplasmic reticulum.
14 All the constructs were verified by DNA sequencing. Monocistronic vectors encoding the human b2-microglobulin, the HLA-A*0201, ICAM-1, LFA-3, and B7.1 molecules were earlier described. 14 
Gene Transfer Procedure
H29/293 GPG packaging cells 19 were transfected with each plasmid by calcium chloride precipitation method. 24 As described earlier, the different cell lines were infected with cell-free retroviral supernatant in the presence of 8 mg/mL of polybrene (Sigma-Aldrich) for 16 hours. Puromycin (Sigma-Aldrich) was added at 5 to 20 mg/mL to the medium for 1 week to select the cells expressing the vector-encoded puromycin-N-acetyltransferase. 14 
Flow Cytometry Analysis
To analyze the phenotype of the AAPCs, fluorescentlabeled antibodies were used against human b2-microglobulin, HLA-A2, CD58 (BD Biosciences, Le-Pont-de-Claix, France), CD54 and CD80 (Invitrogen, Cergy-Pontoise, France). Antibodies against CD66 (human CEA) and MART-1 were purchased from BD Biosciences and Dakocytomation (Trappes, France). Cells were labeled as recommended by the manufacturers.
Intracellular cytokine staining was carried out by incubating T cells with T2 cells loaded with the different peptides (10 mM for 1 h at 371C) or tumor cells at the ratio 1:1 in RPMI containing 1% FCS and 3 mM monensin (SigmaAldrich). For avidity assays done with the anti-CAP1 T-cell clone, T2 cells were loaded with peptide concentrations ranging from 10 mM to 0.1 nM. After 6 hours of co-culture, cells were fixed for 10 minutes in a 4% paraformaldehyde solution and permeabilized with PBS containing 0.1% saponin and 0.5% bovine serum albumin. Then, cells were labeled with anti-IFN-g and anti-CD3 antibodies purchased from Immunotech (Marseille, France). Data were acquired using FACSCalibur cytometer (BD Biosciences).
The anti-CAP1 T-cell clone was labeled with A*0201/ CAP1 or A*0201/FMP Pro5 MHC pentamer (Proimmune, Oxford, UK), as recommended by the manufacturer.
T-cell Purification
PBMCs were isolated by density gradient centrifugation on lymphocyte separation medium (Eurobio Laboratories, Courtaboeuf, France) from HLA-A*0201 + healthy donor or CRC patient peripheral blood with their informed consent and the agreement of the local ethic committee. HLA-A genotyping was realized by standard methods at the Etablissement Francais du Sang (Claude Fe´rec, Brest, France). Blood samples were collected from nonmetastatic CRC patients who did not receive chemotherapy before curative surgery. T cells were purified by rosetting using sheep red blood cells as earlier described.
14 The T-cellenriched population was collected. B cells, monocytes, Natural Killer cells, and activated T cells were depleted by panning on Petri dishes as earlier described. 25 T-cell purity,
as assessed by FACS analysis, was always greater than 98% (data not shown).
Stimulation of Antigen-specific CTLs
Irradiated AAPCs (25 Gy) were plated (10 5 per well) in a 24 well plate the day before stimulation in AIM V medium with 5% DCS (500 mL/well). T cells were resuspended in AIM V medium at a concentration of 2 Â10
6 cells/mL, and 1Â 10 6 T cells were added to the AAPCs and cultured for 14 to 21 days. IL-2 at 20 IU/mL was added to the cocultures after day 7 every second day. For restimulations, T cells were cocultured with AAPCs using the same procedure. 
Cytotoxicity Assays
Standard 51 Cr release assay was done using HLA-A*0201 + T2 cells loaded with the different peptides (10 mM for 1 h at 371C) before labeling with 51 Cr (for 1 h at 371C). For avidity assays done with the anti-CAP1 T-cell clone, T2 cells were loaded with peptide concentrations ranging from 10 mM to 0.1 nM. Five thousand peptide-pulsed, 51 Crlabeled T2 cells were used per well in 96-well U-bottomed plates at different effector to target (E:T) ratios and incubated at 371C for 4 hours. Tumor cell lines were also used as 51 Cr-labeled targets in 4-to 18-hour release assays. Percentage of specific cell lysis was calculated using the standard formula: [(mean experimental cpm-mean spontaneous cpm)/(mean maximum cpm-mean spontaneous cpm)] Â 100. Results are the means of assays done in triplicates.
DNA Sequencing
DNA sequences corresponding to the different peptides, CAP1, CAP1-6D, MART-1, MART-1 modified, and NY-ESO-1, and to the different proteins, CEA, MART-1, and NY-ESO-1 in the different cell lines were verified. DNA was sequenced using Big Dye terminator cycle sequencing kit and ABI prism 3100 DNA sequencer (Applied Biosystems, Foster City, CA).
RESULTS
Construction and Characterization of AAPCs
AAPCs, termed AAPC A2.1 , were generated by sequential transduction of murine fibroblasts NIH/3T3 with monocistronic vectors encoding human b2-microglobulin, HLA-A* 0201, ICAM-1, LFA-3, and B7.1 (Fig. 1A) . The expression of these 5 molecules after transduction was evaluated by flow cytometry. As shown in Figure 1B , these molecules were stably expressed at the surface of all AAPCs. We generated AAPCs expressing different antigenic peptides, CEA-derived CAP1 peptide (AAPC A2.1CAP1 ), CAP1 agonist peptide (AAPC A2.1CAP1-6D ), control peptides derived from MART-1 (AAPC A2.1M1pep ) and from NY-ESO-1 (AAPC A2.1NYpep ) using dicistronic retroviral vectors (Fig.  1A) . In addition, we constructed AAPCs expressing the fulllength antigenic proteins CEA (AAPC A2.1CEA ), MART-1 (AAPC A2.1M1prot ), and NY-ESO-1 (AAPC A2.1NYprot ). For each protein, expression was confirmed by cytometry, Western blot, immunocytochemistry, or immunoassay (Fig. 1B and data not shown) . The integrity of the DNA sequences corresponding to the immunogenic peptides or proteins was verified (Fig. 1C and data not shown) .
AAPCs Expressing CAP1 Peptide, CAP1-6D Peptide, or CEA Protein Do Not Activate CAP1-specific T Cells
Our objective was to activate CAP1-specific T cells with AAPCs. No detectable cytotoxic activity against T2 cells loaded with CAP1 epitope was observed with T cells stimulated with AAPCs expressing the relevant tumorderived peptide, even modified, or the full-length CEA protein, even after 3 or 4 stimulations (Fig. 2) . In contrast, after only 1 stimulation, AAPCs expressing native MART-1 peptide, modified MART-1 peptide (AAPC A2.1M1mod ), or AAPCs Expressing CAP1 or CAP1-6D Peptide but not AAPCs Expressing Full-length CEA Protein Activate a CAP1-specific T-cell Clone
To show that AAPCs indeed efficiently presented CAP1 or CAP1-6D peptide, we took advantage of a specific T-cell clone obtained from a HLA-A*0201 + healthy donor after stimulation with CAP1-6D peptide-pulsed DCs followed by multiple specific restimulations. This CD8 + clone was CAP1 specific as shown by pentamer staining (Fig. 3A) . Peptide titration assays based on IFN-g production (Fig. 3B ) and cytotoxic activity (Fig. 3C) showed that this anti-CAP1 T-cell clone was of high avidity: it could recognize cells loaded with the relevant peptide at nanomolar and even lower concentrations. This avidity was lower than that of the MART-1-specific clone 26 but comparable with that of the NY-ESO-1 specific clone (data not shown) used in this study. As shown in Figure 4A , the anti-CAP1 T-cell clone secreted IFN-g in response to AAPCs transduced with CAP1 or CAP1-6D. Unexpectedly, AAPCs expressing the full length CEA protein were not recognized by this clone. MART-1 and NY-ESO-1 peptide-specific T-cell clones were efficiently stimulated by AAPCs expressing the corresponding peptide or full-length protein.
Tumor Cell Lines Expressing CEA Activate the Anti-CAP1 T-cell Clone Only After Transduction With a Minigene Encoding CAP1 CEA, HLA class I, and HLA-A2 expression by the CRC cell lines was evaluated by flow cytometry (Fig. 4B) . The integrity of the CAP1 epitope sequence in the ). DNA sequences corresponding to antigenic peptides and proteins were verified. In addition, NY-ESO-1 and MART-1 protein expression was determined by Western blot and flow cytometry (data not shown). As earlier seen, parental SW1463 cells were not recognized by the anti-CAP1 T-cell clone. Interestingly, CAP1 expression after transduction in SW1463 cells led to the stimulation of the specific T-cell clone, as assessed by intracellular cytokine (IFN-g) assay (Fig. 5A ). In addition, the T84 cells, only after transduction with vectors encoding HLA-A*0201 molecule and CAP1 peptide, were recognized by the T-cell clone (Fig. 5B , and data not shown). As expected, successful stimulation of NY-ESO-1 and MART-1-specific T-cell clones was obtained with SW1463 cells or HLA-A*0201 + T84 cells expressing the corresponding peptides or fulllength tumor antigens (Fig. 5) .
To show that the negative results obtained with the CRC cell lines were not because of an insufficient level of CEA expression, in the next step, we genetically modified both HLA-A*0201 + CEA À melanoma cell line M102 (MART-1 low , NY-ESO-1 high ) and renal cell carcinoma cell line R104 (MART-1 neg , NY-ESO-1 neg ) using the retroviral vector encoding the full-length CEA protein (M102 CEA , R104 CEA ). Both cell lines expressed higher levels of CEA after CEA-transduction than CEA + CRC cell lines used in this study (Fig. 6A) . IFN-g production and 51 Cr release assays showed that the anti-CAP1-specific T-cell clone was able to context of the HLA-A*0201 molecule. T cells stimulated with AAPC A2.1CEA did not show any detectable cytotoxic activity against HLA-A*0201 + /CEA + cell lines, neither M102 CEA nor any other cell line expressing CEA used in this study even after 18-hour incubations (Fig. 7A and  data not shown) . Similar data have been obtained with 6 CEA (lower panels). E:T ratio: effector to target ratio.
HLA-A*0201 + healthy donors and 6 HLA-A*0201 + CRC patients even after 4 or 5 cycles of stimulation. To address the question whether the absence of response against any epitope derived from CEA could be owing to a negative modulatory role of CEA as described by Shao et al, 27 
AAPC
A2.1M1pep and AAPC M1prot were cotransduced with full-length CEA coding vector (AAPC A2.1M1pepCEA and AAPC A2.1M1protCEA , Fig. 7B ). These AAPCs were as efficient as AAPC A2.1M1pep and AAPC A2.1M1prot to elicit a cytotoxic response against the specific MART-1 peptide (Fig. 7C) .
DISCUSSION
CEA is a potentially attractive tumor antigen to target in cancer immunotherapy, as it is overexpressed in several human cancers, whereas its expression in normal adult tissues is limited. Our AAPC system has been shown to be a promising tool for adoptive immunotherapy, because it can efficiently activate and expand CTLs against not only viral but also tumor-derived epitopes after transduction with the antigenic peptides (gp100 209-217 , MART-1 27-35 , 13 hTERT 540-548 and hTERT 865-873 15 ) or with the whole proteins [pp65, 14 hTERT 15 or WT1 (unpublished data)]. These AAPCs constitute stable cell lines that can be used for any donor or patient sharing the same HLA molecule (present study, HLA-A*0201). Because of their restriction to a single HLA molecule and a single antigen of interest, we could use these AAPCs to further investigate the T-cell response against the peptide CAP1 described as an immunodominant epitope derived from CEA and against other CEA epitopes potentially presented in the HLA-A*0201 context. 8 No cytotoxic response against this epitope was detected after T-cell stimulation with AAPCs expressing CAP1 peptide, the agonist peptide CAP1-6D, or the whole protein CEA. This result was observed after 3 to 4 cycles of stimulation with T cells from HLA-A*0201 + healthy donors or CRC patients. AAPCs were correctly engineered to present antigenic peptides, as confirmed by DNA sequence and protein expression analyses. As earlier described and as shown in this study, AAPCs encoding MART-1 peptide (M1 or M1mod) or full-length protein are able to induce a strong T-cell response against MART-1 from the first stimulation. 14 Moreover, AAPCs expressing MART-1 (peptide or protein), NY-ESO-1 (peptide or protein), CAP1, or CAP1-6D peptide are fully efficient to activate specific T-cell clones. So, it is likely that the absence of anti-CAP1 response in our AAPC system was owing to the poor immunogenicity of this peptide.
Next, we found that the anti-CAP1 T-cell clone failed to recognize not only AAPCs expressing the whole CEA protein but also the HLA-A*0201 + tumor cell lines (CRC, melanoma, or renal cell carcinoma cell lines) expressing CEA naturally or after transduction. On the contrary, this clone was able to recognize the same human tumor cell lines after transduction with a vector encoding the minimal peptide CAP1. The lack of CEA + cell line recognition was not owing to a defect in antigen presentation. All the cell lines expressed the HLA-A2 molecule and the relevant antigen. Moreover, a default in the processing and presentation pathway was excluded in these tumor cell lines, because all of these cell lines expressing naturally or ectopically the full-length tumor antigens MART-1 and NY-ESO-1 could activate T-cell clones specific for the corresponding tumorderived immunodominant peptides. Our results are in agreement with the data published by Schirle et al. 28 Using a biochemical approach, they identified the CEA-derived epitope CEA 694-702 in peptide mixture from HLA-A2 + tumor biopsies or CRC cell line SW1116 but failed to detect CAP1 (605-613) peptide. In addition, Iero et al 20 also observed a lack of tumor recognition of HLA-A*A201 + / CEA + tumor cell lines by CAP1-specific human T cells. These investigators suggested that this might be owing to the low avidity of CAP1-specific T cells that could fail to detect low amounts of CAP1 peptide on tumor cell surface. However, we clearly show that CEA + cell lines transduced with CAP1 minigene are recognized by anti-CAP1 T cells, but that the parental cell lines even if they express CEA at a high level are not. Importantly, the anti-CAP1 T-cell clone we used in this study was of high avidity, at least comparable with that of anti-CAP1 T cells described in the literature. 29, 30 All these findings clearly indicate that the peptide CAP1 is not efficiently processed from the CEA protein not only in AAPCs but also in CRC cell lines. Consequently, our hypothesis is that, if CAP1 is not accessible to the immune system, CAP1-specific T cells can be considered as fully naive T cells having escaped central and/or peripheral tolerance. 13, 31 Importantly, recent publications based on the use of different HLA-A*0201 transgenic mouse models have confirmed the difficulty of generating cytotoxic T cells against CEA. 32, 33 Parkhurst et al 33 even showed that, if it is possible to generate mouse T cells against CAP1, these cells are not able either to recognize human tumor cells expressing CEA. Conversely, they could generate mouse T cells against another CEAderived epitope (691-699) capable of recognizing these same tumor cells.
The discrepancy of our results with data published in other studies may be explained by several reasons. First, regarding CAP1 T-cell stimulation, the work of Schlom's team shows that it is indeed possible to generate anti CAP1 effector T cells but only after in vitro multiple stimulations with the peptide CAP1 and IL-2. 8, 9 Even if CAP1-6D was described as more immunogenic, it is all the same necessary to perform multiple stimulations with this peptide to mount a T-cell response against CAP1. 9 Dendritic cell-based stimulation system has been used by most groups to expand CAP1-specific T cells. 20, 29, [34] [35] [36] It is possible that these professional APCs that express all the costimulatory signals necessary to activate naive or low avidity T cells, were more efficient stimulating cells than AAPCs to mount a CAP1-specific T-cell response. 37 Second, regarding CAP1 T-cell recognition of tumor cells, in several publications, including the princeps study by Schlom et al, the CRC cell line SW403 was used to ascertain tumor cell recognition by anti-CAP1 CTLs. 8, 12, 29, 38 However, data from the literature 39 and from our laboratory (data not shown) indicate that this cell line is not HLA-A*0201 but HLA-A*0205-positive as determined by DNA typing of HLA class I locus A. Tumor reactivity against SW403 cells observed by earlier investigators may then account for a nonspecific allogeneic response rather than for a HLA*A0201-restricted specific anti-tumor response. Finally, in certain studies, the cell lysis level of anti-CAP1 T cells against HLA-A*0201 + CRC cell lines was modest and often obtained during unusually long (18 h) nonstandard cytotoxic assays done with Indium or Europium 8, 34 arguing for the fact that, even if CAP1 were presented by tumor cells, it could be at a too low level to be the target of an efficacious specific T-cell response.
Using AAPCs expressing the full-length CEA antigen, we did not detect any cytotoxic T-cell response against CEA + cell lines, regardless of the epitope, even after multiple stimulations of T cells from HLA-A*0201 + healthy donors or CRC patients. This absence of T-cell response against CEA antigen is unlikely to be owing to a processing default in stimulating cells. Indeed, AAPCs have all the cellular machinery to degrade antigenic proteins and to present MHC class I-restricted antigenic peptides, as shown here with MART-1 and NY-ESO-1 full-length proteins or as earlier described for cytomegalovirus, 15 hTERT, 16 and WT-1 antigens (unpublished data). This absence of T-cell response against CEA antigen is unlikely to be owing either to a negative immunomodulatory role of this molecule, as the expression of CEA by AAPCs already encoding MART-1 (peptide or protein) did not affect the generation of specific T cells against this latter antigen in our AAPC system. It should be kept in mind that CEA is a self antigen expressed not only during fetal life but also, albeit at a low level, in normal adult tissues. Our hypothesis is that selfreactive T cells of the highest avidity for CEA antigen are deleted through central tolerance. 40 If T cells of lower avidity remain in the periphery, they could be kept unresponsive by multiple mechanisms of peripheral tolerance limiting the potential ability of our AAPCs, although expressing the main costimulatory molecules, to generate T cells against this auto-antigen. 41 Noteworthy, to overcome the difficulty of generating CEA specific T cells in humans, Parkhurst et al 33 have described an elegant way of redirecting human T cells by gene transfer of a CEA (691-699) reactive mouse TCR modified to improve recognition of the antigen for immunotherapy.
In summary, our study shows that CAP1, even if we cannot exclude its presence at a very low level on tumor cell surface, is not efficiently presented by HLA-A*0201-positive cells expressing CEA. The existence of truly naive T cells against CAP1 may explain its poor immunogenicity and its inefficiency. On the other hand, the absence of T-cell response we observed against other CEA-derived epitopes in our AAPC system is probably owing to different
